Considering these findings, targeting the melatonin pathway and the glucocorticoid receptor, both of which are implicated in CRD, may provide new opportunities to impair PCa growth and overcome therapeutic resistance, respectively. The gene discussed is NR3C1; the disease is posterior cortical atrophy.